United Therapeutics Corporation logo

United Therapeutics Corporation (UTHR)

Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
549. 47
+9.42
+1.74%
$
24.23B Market Cap
11.96 P/E Ratio
- Div Yield
314,188 Volume
24.04 Eps
$ 540.05
Previous Close
Add Transaction
Day Range
541.1 551.89
Year Range
272.12 609.35
Want to track UTHR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 11 months ago
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 11 months ago
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks | 11 months ago
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?

Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Executive Vice President, Product Development and Xenotransplantation James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Joseph Thome - TD Cowen Jessica Fye - JPMorgan Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Roger Song - Jefferies Ash Verma - UBS Operator Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today.

Seekingalpha | 1 year ago
United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say

United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $6.63 per share, beating the Zacks Consensus Estimate of $6.29 per share. This compares to earnings of $6.17 per share a year ago.

Zacks | 1 year ago
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?

United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks | 1 year ago
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript

Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations Dewey Steadman - Head, IR Conference Call Participants Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2024 Corporate Update. My name is Cindy, and I will be your conference operator today.

Seekingalpha | 1 year ago
Loading...
Load More